Development and Automation of a 384-Well Cell Fusion Assay to Identify Inhibitors of CCR5/CD4-Mediated HIV Virus Entry

Abstract

This article describes the automation of an in vitro cell-based fusion assay for the identification of novel inhibitors of receptor mediated HIV-1 entry. The assay utilises two stable cell lines: one expressing CD4, CCR5 and an LTR-promoter/β-galactosidase reporter construct, and the other expressing gp160 and tat. Accumulation of β-galactosidase can only occur following fusion of these two cell lines via the gp160 and receptor mediators, as this event facilitates the transfer of the tat transcription factor between the two cell types. Although similar cell fusion systems have been described previously, they have not met the requirements for HTS due to complexity, throughput and reagent cost. The assay described in this article provides significant advantage, as (a) no transfection/infection events are required prior to the assay, reducing the potential for variability, (b) cells are mixed in solution, enhancing fusion efficiency compared to adherent cells, (c) miniaturisation to low volume enables screening in 384-well plates; and (d) online cell dispensing facilitates automated screening. This assay has been employed to screen ~650,000 compounds in a singleton format. The data demonstrate that the assay is robust, with a Z′ consistently above 0.6, which compares favourably with less complex biochemical assays.

Keywords

HIV HTS gp120 CD4 CCR5

References

1. Gillim L , Gusella GL , Vargas J Jr , Marras D , Koltman ME , Cara A : Development of a novel screen for protease inhibitors. Clin Diag Lab Immunol 2001;8(2):437-440.

2. Zhang J-H , Chen T , Nguyen SH , Oldenburg KR : A high-throughput homogeneous assay for reverse transcriptase using generic reagents and time-resolved fluorescence detection. Anal Biochem 2000;281(2):182-186.

3. Cummings RT , McGovern HM , Zheng S , Park YW , Hermes JD : Use of a phosphotyrosine-antibody pair as a general detection method in homogeneous time-resolved fluorescence: application to human immunodeficiency viral protease. Anal Biochem 1999;269(1):79-93.

4. Lorenzi P , Yerly S , Abderrakim K , Fathi M , Rutschman OT , von Overbeck J , et al: Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritanovir plus saquinavir. Swiss HIC Cohort Study. AIDS 1997;11(12):F95-F99.

5. Moyle G : Clinical manifestations and management of antiretroviral nucleoside analog-related mitchondrial toxicity. Clin Ther 2000;22(8):911-936.

6. Pillay D , Taylor S , Richman DD : Incidence and impact of resistance against approved antiretroviral drugs. Rev Med Virol 2000;10(4):231-253.

7. Shafer RW : Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002;15(2):247-277.

8. Chan DC , Kim PS : HIV entry and its inhibition. Cell 1998;93:681-684.

9. Moore JP , Trkola A , Dragic T : Co-receptors for HIV-1 entry. Curr Opin Immunol 1997;9(4):549-550.

10.

10. Xiao X , Wu L , Stantchev TS , Feng Y-R , Ugolini S , Chen H , et al: Constitutive cell surface association between CD4 and CCR5. Proc Natl Acad Sci U S A 1999;96:7496-7501.

11.

11. Beutler JA , McMahon JB , Johnson TR , O’Keefe BR , Buzzell RA , Robbins D , et al: High-throughput screening for cyanovirin-N mimetics binding to HIV gp41. J Biomol Screening 2002;7(2):105-110.

12.

12. McMahon JB , Beutler JA , O’Keefe BR , Goodrum CB , Myers MA , Boyd MR : Development of a cyanovirin-N/HIV-1 gp120 binding assay for high throughput screening of natural products by time-resolved fluorescence. J Biomol Screening 2000;5(3):169-176.

13.

13. Shiraishi M , Aramaki Y , Seto M , Imoto H , Nishikawa Y , Kanzaki W , et al: Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J Med Chem 2000;43(10):2049-2063.

14.

14. Jiang S , Zhao Q , Debnath AK : Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des 2002;8(8):563-580.

15.

15. Jiang S , Lin K , Zhang L , Debnath AK : A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J Virol Methods 1999;80(1):85-96.

16.

16. Cairns JS , D’Souza MP : Chemokines and HIV-1 second receptors: the therapeutic connection. Nature Med 1998;4(5):563-568.

17.

17. Baik SSW , Doms RW , Doranz BJ : HIV and SIV gp120 binding does not predict co-receptor function. Virology 1999;259(2):267-273.

18.

18. Chiba H , Asanuma S , Okamoto M , Inokoshi J , Tanaka H : A simple screening system for anti-HIV drugs: syncytium formation assay using T-cell line tropic and macrophage tropic HIV env expressing cell lines—establishment and validation. J Antibiotics 2001;54(10):818-826.

19.

19. Hong YL , Wu LH , Cui M , McMaster G , Hunt SW , Chung F-Z : New reporter cell lines to study macrophage-tropic HIV envelope protein-mediated cell-cell fusion. AIDS Res Hum Retrovirus 1999;15(18):1667-1672.

20.

20. Pine PS , Weaver JL , Oravecz , Pall M , Ussery M , Aszalos A : A semi-automated fluorescence based cell-to-cell fusion assay for gp120-gp41 and CD4 expressing cells. Exp Cell Res 1998;240(1):49-57.

21.

21. Reeves JD , Gallo SA , Ahmad N , Miamidian JL , Harvey PE , Sharron M , et al: Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A 2002;99(25):16249-16254.

22.

22. Falconer M , Smith F , Surah-Narwal S , Congrave G , Liu Z , Hayter P , et al: High-throughput screening for ion channel modulators. J Biomol Screening 2002;7(5):460-465.

23.

23. Wright PA , Boyd HF , Bethell RC , Busch M , Gribbon P , Kraemer J , et al: Development of a 1 μl scale assay for mitogen-activated kinase kinase 7 using 2D-fluorescence intensity distribution analysis anisotropy. J Biomol Screening 2002;7(5):419-428.